ImmunityBio/$IBRX
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About ImmunityBio
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Ticker
$IBRX
Sector
Primary listing
Employees
688
Headquarters
Website
ImmunityBio Metrics
BasicAdvanced
$8.7bn
-
-$0.38
0.06
-
Price and volume
Market cap
$8.7bn
Beta
0.06
52-week high
$12.43
52-week low
$1.83
Average daily volume
15m
Financial strength
Current ratio
5.099
Quick ratio
4.622
Long term debt to equity
-167.219
Total debt to equity
-169.088
Interest coverage (TTM)
-2.15%
Profitability
EBITDA (TTM)
-226.602
Gross margin (TTM)
99.34%
Net profit margin (TTM)
-310.18%
Operating margin (TTM)
-226.00%
Effective tax rate (TTM)
0.04%
Revenue per employee (TTM)
$160,000
Management effectiveness
Return on assets (TTM)
-34.19%
Return on equity (TTM)
71.17%
Valuation
Price to revenue (TTM)
68.043
Price to book
-16.94
Price to tangible book (TTM)
-16.48
Price to free cash flow (TTM)
-24.931
Free cash flow yield (TTM)
-4.01%
Free cash flow per share (TTM)
-0.336
Growth
Revenue change (TTM)
668.31%
Earnings per share change (TTM)
-38.27%
3-year revenue growth (CAGR)
678.62%
3-year earnings per share growth (CAGR)
-28.42%
What the Analysts think about ImmunityBio
Analyst ratings (Buy, Hold, Sell) for ImmunityBio stock.
ImmunityBio Financial Performance
Revenues and expenses
ImmunityBio Earnings Performance
Company profitability
ImmunityBio News
AllArticlesVideos
ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million
Business Wire·2 hours ago
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Newsfile Corp·22 hours ago
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
Newsfile Corp·22 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ImmunityBio stock?
ImmunityBio (IBRX) has a market cap of $8.7B as of May 07, 2026.
What is the P/E ratio for ImmunityBio stock?
The price to earnings (P/E) ratio for ImmunityBio (IBRX) stock is 0 as of May 07, 2026.
Does ImmunityBio stock pay dividends?
No, ImmunityBio (IBRX) stock does not pay dividends to its shareholders as of May 07, 2026.
When is the next ImmunityBio dividend payment date?
ImmunityBio (IBRX) stock does not pay dividends to its shareholders.
What is the beta indicator for ImmunityBio?
ImmunityBio (IBRX) has a beta rating of 0.06. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.